Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: initial considerations

Carmo, Fagner Santos do; Ricci-Júnior, Eduardo; Cerqueira-Coutinho, Cristal; Albernaz, Marta de Souza; Bernardes, Emerson Soares; Missailidis, Sotiris; Santos-Oliveira, Ralph

doi:10.2147/ijn.s118482

Cited by 34 publications

(13 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A MUC1 antibody, C595, in association with docetaxel, significantly decreased tumor growth in a xenograft model of ovarian cancer by augmenting apoptosis and necrosis 47 . MUC1 was also used as a therapeutic target for triple-negative breast cancer using anti-MUC1 aptamer as a drug delivery system for a radioactive polymeric nanoparticle 48 . Further, dendritic cell (DC)-based vaccine has been used as an alternative approach targeting MUC1 in cancer cells.…”

Section: Discussionmentioning

confidence: 99%

A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer

Wu¹,

Kim²,

Kim³

et al. 2018

Theranostics

View full text Add to dashboard Cite

Background: Mucin1 (MUC1) is a highly glycosylated transmembrane protein that has gained attention because of its overexpression in various cancers. However, MUC1-targeted therapeutic antibodies have not yet been approved for cancer therapy. MUC1 is cleaved to two subunits, MUC1-N and MCU1-C. MUC1-N is released from the cell surface, making MUC1-C a more reasonable target for cancer therapy. Therefore, we produced a monoclonal antibody (anti-hMUC1) specific to the extracellular region of MUC1-C and evaluated its effects in vitro and in vivo.Methods: We produced a monoclonal antibody (anti-hMUC1) using a purified recombinant human MUC1 polypeptide and our novel immunization protocol. The reactivity of anti-hMUC1 was characterized by ELISA, western blotting and immunoprecipitation analyses. The localization of the antibody in the breast cancer cells after binding was determined by confocal image analysis. The effects of the antibody on the growth of cells were also investigated. We injected anti-hMUC1 and performed in vivo tracing analysis in xenograft mouse models. In addition, expression of MUC1 in tissue sections from patients with breast cancer was assessed by immunohistochemistry with anti-hMUC1.Results: The anti-hMUC1 antibody recognized recombinant MUC1 as well as native MUC1-C protein in breast cancer cells. Anti-hMUC1 binds to the membrane surface of cells that express MUC1 and is internalized in some cancer cell lines. Treatment with anti-hMUC1 significantly reduced proliferation of cells in which anti-hMUC1 antibody is internalized. Furthermore, the anti-hMUC1 antibody was specifically localized in the MUC1-expressing breast cancer cell-derived tumors in xenograft mouse models. Based on immunohistochemistry analysis, we detected significantly higher expression of MUC1 in cancer tissues than in normal control tissues. Conclusion: Our results reveal that the anti-hMUC1 antibody targets the extracellular region of MUC1-C subunit and may have utility in future applications as an anti-breast cancer agent.

show abstract

Section: Discussionmentioning

confidence: 99%

A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer

Wu¹,

Kim²,

Kim³

et al. 2018

Theranostics

View full text Add to dashboard Cite

show abstract

“…The results showed that the system was able to accumulate specifically in the tumor, generating an excellent SPECT image. Furthermore, the authors suggested that an alteration of the 99m Tc radionuclide by a β (177-Luthetium) or α emitter (223 Radium) could promote a therapeutic effect on the tumor (Carmo et al., 2017 ). In order to develop a theragnostic nanostructure for esophageal cancer, Gill et al.…”

Section: Radioactive Polymeric Nanoparticles For Biomedical Applicatimentioning

confidence: 99%

Radioactive polymeric nanoparticles for biomedical application

Wu¹,

Helal-Neto

Matos

et al. 2020

Drug Delivery

Self Cite

View full text Add to dashboard Cite

Nowadays, emerging radiolabeled nanosystems are revolutionizing medicine in terms of diagnostics, treatment, and theranostics. These radionuclides include polymeric nanoparticles (NPs), liposomal carriers, dendrimers, magnetic iron oxide NPs, silica NPs, carbon nanotubes, and inorganic metal-based nanoformulations. Between these nano-platforms, polymeric NPs have gained attention in the biomedical field due to their excellent properties, such as their surface to mass ratio, quantum properties, biodegradability, low toxicity, and ability to absorb and carry other molecules. In addition, NPs are capable of carrying high payloads of radionuclides which can be used for diagnostic, treatment, and theranostics depending on the radioactive material linked. The radiolabeling process of nanoparticles can be performed by direct or indirect labeling process. In both cases, the most appropriate must be selected in order to keep the targeting properties as preserved as possible. In addition, radionuclide therapy has the advantage of delivering a highly concentrated absorbed dose to the targeted tissue while sparing the surrounding healthy tissues. Said another way, radioactive polymeric NPs represent a promising prospect in the treatment and diagnostics of cardiovascular diseases such as cardiac ischemia, infectious diseases such as tuberculosis, and other type of cancer cells or tumors.

show abstract

“…Santos do Carmo et al used a technetium-99m-labeled silica-based polymeric nanoparticle loaded with anti-MUC1 aptamers to deliver drugs and radiolabel triple negative breast cancer (TNBC). Biodistribution studies showed that the nanoparticle-aptamer construct was highly absorbed by the intestine (30%), but was also taken up by the tumor (5%), which is a high rate for targeted drug delivery [ 140 ]. In contrast to the use of silica nanoparticles, Yu et al successfully used MUC1 aptamers to deliver anti-cancer paclitaxel-loaded liposomal formulations to MCF-7 cells [ 141 ].…”

Section: Development Of Cancer-specific Aptamers For Diagnosismentioning

confidence: 99%

Current Advances in Aptamers for Cancer Diagnosis and Therapy

Hori

Herrera

Rossi

et al. 2018

Cancers

137

103

View full text Add to dashboard Cite

Nucleic acid aptamers are single-stranded oligonucleotides that interact with target molecules with high affinity and specificity in unique three-dimensional structures. Aptamers are generally isolated by a simple selection process called systematic evolution of ligands by exponential enrichment (SELEX) and then can be chemically synthesized and modified. Because of their high affinity and specificity, aptamers are promising agents for biomarker discovery, as well as cancer diagnosis and therapy. In this review, we present recent progress and challenges in aptamer and SELEX technology and highlight some representative applications of aptamers in cancer therapy.

show abstract

Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: initial considerations

Cited by 34 publications

References 40 publications

A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer

A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer

Radioactive polymeric nanoparticles for biomedical application

Current Advances in Aptamers for Cancer Diagnosis and Therapy

Contact Info

Product

Resources

About